Cognitive alterations in juvenile Parkinson´s disease caused by the C212Y mutation in the Parkin gene.

In Antioquia, Colombia, four families have been reported with juvenile Parkinson´s disease and carrying the C212Y mutation in the Parkin gene. Many cognitive alterations associated with idiopathic, late-onset Parkinson´s disease have been described; however, little attention has been paid to the description of neuropsychological profiles in families carrying mutations in genes associated with juvenile Parkinson´s disease. For this study we selected a group of ten homozygous carriers of Parkin mutation C212Y with the clinical and a group of molecular diagnosis of Parkinson´s disease, and ten healthy relatives as controls. The neuropsychological evaluation revealed statistically significant differences between the two groups (p < 0.05) in Minimental State Examination and in tests evaluating working memory and attention in which prolonged execution times and marked slowing down of information processing were observed. We suggest that the observed alterations could be considered as neuropsychological features of patients with the C212Y mutation in the Parkin gene, the phenotypic expression of which seems to be associated in this population with slow evolution, mild cognitive impairment and functional involvement

Alteraciones cognitivas en Parkinson Juvenil causado por la mutación C212Y en el gen Parkin

In Antioquia, Colombia, four families have been reported with juvenile Parkinson´s disease and carrying the C212Y mutation in the Parkin gene. Many cognitive alterations associated with idiopathic, late-onset Parkinson´s disease have been described; however, little attention has been paid to the description of neuropsychological profiles in families carrying mutations in genes associated with juvenile Parkinson´s disease. For this study we selected a group of ten homozygous carriers of Parkin mutation C212Y with the clinical and a group of molecular diagnosis of Parkinson´s disease, and ten healthy relatives as controls. The neuropsychological evaluation revealed statistically significant differences between the two groups (p < 0.05) in Minimental State Examination and in tests evaluating working memory and attention in which prolonged execution times and marked slowing down of information processing were observed. We suggest that the observed alterations could be considered as neuropsychological features of patients with the C212Y mutation in the Parkin gene, the phenotypic expression of which seems to be associated in this population with slow evolution, mild cognitive impairment and functional involvement.En Antioquia (Colombia) hay reportadas cuatro grandes familias afectadas con enfermedad de Parkinson Familiar Juvenil portadoras de la mutación C212Y en el gen Parkin. Nosotros seleccionamos un grupo de 10 sujetos con diagnóstico de enfermedad de Parkinson (EP), portadores de la mutación C212Y y un grupo de 10 familiares sanos (no portadores). En el ámbito neuropsicológico se evidencian diferencias significativas entre los grupos (p<0.05) en el minimental state, y en pruebas que evalúan la memoria inmediata y la atención, observandose tiempos prolongados de ejecución y marcada lentificación. Esta investigación sugiere que las alteraciones observadas podrían ser consideradas como rasgos neuropsicológicos de los pacientes con la mutación C212Y en el gen Parkin, cuya expresión fenotípica en esta población parece estar asociada con una lenta evolución y a deterioro cognitivo leve (DCL)

Libro conmemorativo de los doscientos años de creación de la corte de almirantazgo de Venezuela

La presente publicación se estructura en 29 capítulos distribuidos en tres partes, la primera contiene las contribuciones históricas, la segunda, reflexiones sobre varios aspectos de la realidad del ámbito jurídico marítimo venezolano y la tercera doctrina sobre diversos temas de Derecho Marítimo

Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial

Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac®, an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity, preventing severe COVID-19 cases. We investigate the safety and non-inferiority of two immunization schedules of CoronaVac® in a non-inferiority trial in healthy adults. A total of 2302 healthy adults were enrolled at 8 centers in Chile and randomly assigned to two vaccination schedules, receiving two doses with either 14 or 28 days between each. The primary safety and efficacy endpoints were solicited adverse events (AEs) within 7 days of each dose, and comparing the number of cases of SARS-CoV-2 infection 14 days after the second dose between the schedules, respectively. The most frequent local AE was pain at the injection site, which was less frequent in participants aged ≥60 years. Other local AEs were reported in less than 5% of participants. The most frequent systemic AEs were headache, fatigue, and myalgia. Most AEs were mild and transient. There were no significant differences for local and systemic AEs between schedules. A total of 58 COVID-19 cases were confirmed, and all but 2 of them were mild. No differences were observed in the proportion of COVID-19 cases between schedules. CoronaVac® is safe, especially in ≥60-year-old participants. Both schedules protected against COVID-19 hospitalization

Delaying surgery for patients with a previous SARS-CoV-2 infection

Not availabl